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Abstract  1 
 Objectives. Infection with oncogenic human papillomaviruses (HPV) is a prerequisite 2 
for the development of cervical cancer. In many cases of cervical cancer and all cervical 3 
cancer derived cell lines oncogenic HPV DNA is found to be integrated, indicating the 4 
importance of integration in disease development. In this study, 176 HPV 16 positive 5 
precancerous cervical lesions were analyzed for the physical state of viral genome to 6 
determine the sites of integration into a host cell DNA and to evaluate the incidence of the 7 
integration in different stages of cervical lesions.  8 
 Methods. The detection of integrated papillomavirus sequences (DIPS) method in 9 
combination with the amplification by polymerase chain reaction (PCR) of E1/E2 region was 10 
used to identify the physical state of HPV 16 genome. The site of integration within a host 11 
cell genome was determined by sequencing of DIPS unusual sized amplicons.   12 
Results. The combined results of DIPS and E1/E2 PCR revealed the integration of 13 
HPV 16 DNA in 7.4% samples. The integration was found only in high grade cervical lesions 14 
indicating that it is a late event in disease progression. Sequencing of 11 DIPS amplicons 15 
revealed HPV DNA from six samples (54.5%) to be integrated in cellular genes (VMP1, 16 
PVRL1, CHERP, CEACAM5, AHR, MRF-2) and also 6 (54.5%) within the common fragile 17 
sites (CFS).  18 
 Conclusions. Although, the HPV integration is known to be a random event, this 19 
study indicates that HPV 16 integrates more than chance within or close to CFSs. As most of 20 
the genes affected by HPV 16 integration can be linked with some aspects of tumor 21 
formation, this indicates that the site of HPV DNA integration might play a role in the rate 22 
and the nature of tumor development.  23 
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Introduction 1 
Infection with oncogenic human papillomaviruses (HPV) is a prerequisite for the 2 
development of cervical cancer [1]. HPV DNA is detected in almost every (99.7%) cervical 3 
cancer sample analyzed [2] with HPV 16 being the most common type of HPV found in 4 
cervical cancer samples [3]. Cervical cancer develops through several precancerous stages, 5 
namely, cervical inthraepithelial neoplasia grades 1 to 3 (CIN 1-3). Cervical cancer usually 6 
develops through several decades and only in a small fraction of women infected with 7 
oncogenic HPV types, which indicates involvement of other factors, besides HPV infection. 8 
However, other risk factors involved in the development of cervical cancer remain unknown. 9 
The integration of viral DNA in the genome of human cells is considered as one of the steps 10 
that lead to the progression of the precancerous lesion into cancer. Moreover, there are several 11 
consequences of viral integration that could lead to tumor progression. It has been established 12 
that integration of viral DNA in the cellular genome provides selective growth advantage to 13 
cervical epithelial cells [4]. Upon integration viral E2 transcription repressor gene is often lost 14 
or disrupted leading to deregulation of E6 and E7 oncogene transcription [5-7]. In addition, 15 
viral transcription from integrated viral DNA can be deregulated as the result of cis-acting 16 
host sequences [8] or differences in chromatin structure at the promoter site [9], again leading 17 
to an increased viral oncogenes production. The recent studies suggest that integration may 18 
also have additional effect on the progression of precancerous lesions to cancer by insertional 19 
mutagenesis [10]. 20 
The site of integration within genome is random, although preferential integration in 21 
common fragile sites (CFS) have been proposed [11]. However, since these sites are prone to 22 
breaks and different kinds of genetic rearrangements the preferential integration within CFS is 23 
considered merely to be the consequence of their facile accessibility [12]. 24 
 5 
The goal of this study was to determine the frequency and the sites of integration 1 
within the human genome in the precancerous lesions of the cervix ranging from atypical and 2 
mild to high grade lesions.  3 
 4 
Material and methods 5 
Clinical samples 6 
Cervical samples were collected from women attending the outpatient unit of the 7 
Clinic of Gynecology and Obstetrics of the University Hospital “Sestre Milosrdnice” (Zagreb, 8 
Croatia). Cervical swabs were taken from women with cytological abnormalities determined 9 
by Pap-smear for the purpose of HPV detection and genotyping, according to the Croatian 10 
protocol for the management of women with precancerous cervical lesions [13]. A subset (N 11 
= 176) of HPV 16 positive samples determined by the previously established protocol of HPV 12 
DNA detection and typing [14] was used in this study. Examinees were 17 to 50 years old 13 
(mean age 30 years). The cytological diagnosis of cervical specimens was determined 14 
according to the Croatian classification of cervical smears “Zagreb 2002” [15] that is in line 15 
with the “2001 Bethesda” system for reporting Pap test results. In the study group there were 16 
39 (22.2%) women with atypical squamous cells of unknown significance (ASCUS), 32 17 
(18.2%) with CIN 1 (also nominated as low-grade squamous intraepithelial lesions, i.e. 18 
LSIL), 46 (26.1%) with CIN 2 (classified as high-grade squamous intraepithelial lesions, i.e. 19 
HSIL), 48 (27.3%) with CIN 3 (also classified as HSIL), and 11 (6.3%) with an unknown 20 
diagnosis. The study was approved by the Ethical Board of Rudjer Boskovic Institute.   21 
DNA isolation 22 
Cervical swabs were resuspended in lysis buffer (10 mM Tris-HCl, pH 7.5, 1 mM 23 
EDTA, pH 7.9, 0.5 % SDS) and treated overnight at 37°C with proteinase K (100 μg/ml). 24 
 6 
Standard phenol-chloroform extraction and ethanol precipitation were used for DNA 1 
purification, and pelleted DNA was resuspended in 50-100 L of tridistillated sterile water 2 
and stored at -20C. In order to determine the quality and the quantity of isolated DNA, each 3 
DNA was analyzed by electrophoresis on 1% agarose gels stained with ethidium bromide and 4 
spectrophotometrically.  5 
DIPS PCR  6 
To determine the physical state of HPV 16 DNA and site of integration within the cell 7 
genome the DIPS (detection of integrated papillomavirus sequences) [16] PCR (polymerase 8 
chain reaction) based method with our modifications was used. Briefly, 0.6 μg of sample 9 
DNA was digested with Sau3A I or Taq I enzymes at 37°C by overnight incubation. Enzyme 10 
was inactivated by heating for 20 minutes at 65°C or 80°C for Sau3A I or Taq I enzyme, 11 
respectively.  12 
After digestion, 50 pmol of adapter oligonucleotides AS-Taq I (17 bp sequence: 13 
CGCAACGTGTAAGTCTG-NH2) or AS-Sau3A I (19 bp sequence: 14 
GATCCAACGTGTAAGTCTG-NH2) annealed to AL oligonucleotide (45 bp: 15 
GGGCCATCAGTCAGCAGTCGTAGCCGGATCCAGACTTACACGTTG) were ligated to 16 
the digested sample DNA in a 20 μl reaction with 2 U T4 DNA ligase (Roche) and incubated 17 
at 16°C for one hour.  18 
Seven downstream and 8 upstream HPV 16 type-specific primers were used for the 19 
linear amplification of HPV 16 DNA, (Table 1). PCR reaction was performed in 20 μl 20 
reactions, containing 1 μl ligated sample DNA, 2 μl 10X PCR buffer, 0.2 mM of each dNTP 21 
2.0 mM MgCl2, 0.25 μM of primer and 0.125 U Ex-Taq DNA polymerase (Takara). The 22 
relative positions of PCR primers on the HPV genome are presented on Figure 1. Following 23 
cycling conditions for amplification were used: denaturation for 2 minutes at 94°C, 25 cycles 24 
 7 
of 30 second denaturation at 94°C, 45 second annealing at 60°C and 2 minutes elongation at 1 
72°C increased by 1 second per cycle. The PCR reaction was followed by final elongation for 2 
5 minutes at 72°C. The amplification was performed in Gene Amp PCR System 2400 3 
(Applied Biosystems).  4 
A second exponential PCR was performed using 16 nested HPV primers (Table 1) and 5 
an adapter specific primer, AP (sequence: GGCCATCAGTCAGCAGTCGTAG). PCR 6 
reaction was performed in 20 μl containing 1 μl product of the first reaction, 0.25 μM of HPV 7 
specific and adapter specific primers, with the remaining reagents being identical to the first 8 
reaction. PCR cycling conditions were the same as for the first reaction. For some samples it 9 
was impossible to determine the genome state so a second restriction assay with Taq I was 10 
performed. Linear amplification of HPV DNA containing restricted fragments was performed 11 
using 6 downstream (DIPS1/DIPS1N, DIPS2/DIPS2N, DIPS3/DIPS3N, DIPS8/DIPS8N, 12 
DIPS9/DIPS9N, DIPS10/DIPS10N) and 6 upstream primers (DIPS4/DIPS4N, 13 
DIPS5/DIPS5N, DIPS6/DIPS6N, DIPS7/DIPS7N, DIPS11/DIPS11N, DIPS12/DIPS12N) 14 
(Table 1 and Figure 1). The PCR reaction conditions and cycling parameters for both linear 15 
and exponential reactions remain the same. For extrachromosomal HPV 16 it is possible to 16 
predict the size of all produced PCR amplicons as positions of restriction enzyme cutting are 17 
known; Sau3A I cuts at nucleotide positions 525, 622, 871, 3480, 4364, 4523, 4541, 5073, 18 
5237, 6154, 6954, 7017 and Taq I at position 505 for the referent HPV16 sequence and 19 
additionally at positions 2608 or 3118 for HPV 16 variants (Figure 1).  20 
The PCR amplicons were resolved by agarose gel electrophoresis (1 or 2%, depending 21 
on the amplicon size); those deviating from the expected size were sequenced to determine if 22 
they are generated from integrated HPV genomes.  23 
 8 
PCR amplification of E1/E2 gene of HPV 16 DNA 1 
The E1/E2 PCR was performed according to Yoshinouchi et al. [17] and Lukaszuk et 2 
al. [18], who describe the protocols for E1 and E2 gene amplification, respectively. Briefly, 2 3 
pairs of PCR primers were used: E1A (ATGTTACAGGTAGAAGGGCG; 5’ nt 1293) with 4 
E1B (TGCTGCCTTTGCATTACTAG; 5’ nt 1463) and E2A 5 
(TGCACCAACAGGATGTATAA; 5’ nt 3066) with E2B (TCAACTTGACCCTCTACCAC; 6 
5’ nt 3193) amplifying 189 and 147 bp regions of the E1 and E2 genes, respectively. The 7 
reactions were performed in 20 μL, containing 100 ng sample DNA, 2 μL 10x PCR buffer, 8 
0.2 mM each dNTP, 2.0 mM MgCl2, 0.25 μM each primer and 0.125 U Taq DNA-9 
polymerase. The following amplification conditions were used: denaturation for 10 minutes at 10 
95°C, 35 cycles of 30 second denaturation at 95°C, 45 second annealing at 55°C and 1 11 
minutes elongation at 72°C increased by 1 second per cycle. The PCR reaction was followed 12 
by final elongation for 5 minutes at 72°C. The amplicons were resolved by 2% gel 13 
electrophoresis.  14 
Sequence analysis 15 
The DIPS amplicon sizes different from expected were sequenced to determine the 16 
place of integration in the host cell genome. PCR product was excised from 1 to 2% agarose 17 
gel, depending on the size of the amplicon, and purified using QIAquick PCR Purification Kit 18 
according to the manufacturer’s instructions (Qiagen GmbH). Five hundred ng of sample was 19 
sequenced with the forward and reverse primers. The BigDye Terminator v1.1 Cycle 20 
Sequencing Kit (Applied Biosystems) was used. The products were analyzed with ABI 21 
PRISM 3100 Genetic Analyzer (Applied Biosystems) using Sequencing Analysis 5.1 program 22 
(Applied Biosystems). The obtained sequences were compared with sequences in the NCBI 23 
database (http://www.ncbi.nlm.nih.gov/) using BLAST program from the same website to 24 
determine if they contain human DNA sequences. Human sequences from the integrated 25 
 9 
samples were further analyzed in NCBI-Map Viewer 1 
(http://www.ncbi.nlm.nih.gov/mapview/) or UCSC Genome Bioinformatics 2 
(http://genome.ucsc.edu/) to determine the actual chromosome and the region in which HPV 3 
16 was integrated.  4 
Statistical analysis 5 
 The results obtained by different methods were entered and processed manually into 6 
Microsoft Excel on a personal computer. The differences between study groups were 7 
evaluated by Chi-square (2) test (GraphPad Prism version 4.00 for Windows, GraphPad 8 
Software, San Diego California USA), with p value under 0.05 being statistically significant. 9 
 10 
Results  11 
Using the DIPS method, 176 HPV 16 positive DNA samples from patients with 12 
different grades of cervical neoplasia were analyzed. Using Sau3A I restriction enzyme, it was 13 
impossible to determine the HPV genome state in all samples. Samples in which the analysis 14 
with Sau3A I enzyme failed or gave undetermined result were additionally analyzed with Taq 15 
I restriction enzyme digestion.  16 
If the HPV genome is present in the extrachromosomal form in the sample, DIPS PCR 17 
should amplify DNA of expected size. Failure to amplify DNA or amplification of different 18 
fragment size than expected suggests that the HPV genome might be integrated. To verify this 19 
assumption such PCR products were sequenced. In 10 of 176 samples (5.7%), sequencing 20 
confirmed the presence of only HPV DNA, even though the PCR product was of an unusual 21 
size. It appears that those samples contained HPV 16 variants with internal rearrangements 22 
and/or gain or loss of Sau3A I or Taq I restriction site (data not shown). Using the described 23 
methods, the status of HPV genomes was determined in 146 of 176 (82.9%) samples, 8 of 24 
 10 
which (5.5%) were shown to be integrated, 3 (2%) were shown to contain both 1 
extrachromosomal and integrated forms, and the remaining 135 (92.5%) had 2 
extrachromosomal HPV genomes.  3 
Both Sau3A I and Taq I based DIPS assays failed to resolve the HPV genome status of 4 
30 of 176 (17.1%) samples. In 23 of 30 samples, the amplification of large DIPS amplicons 5 
was unsuccessful due to unknown reasons, but most likely because of the fragmentation 6 
(degradation) of sample DNA as the short amplicons of E1/E2 PCR were successfully 7 
obtained from those samples. In addition, in 7 of 30 samples, only some of all target large 8 
DIPS amplicons were amplified and in 2 of those 7 samples there were amplicons suggesting 9 
integration of HPV 16 DNA. However, the sequencing of the DIPS amplicons supposedly 10 
containing human DNA sequences was unsuccessful, leaving those 7 samples with 11 
inconclusive result, also. 12 
The unsuccessful amplification of E1 and/or E2 genes indicates whether those genes 13 
are disrupted because of the HPV genome integration into a host cell genome. In this study, 14 
the E1/E2 PCR analysis has shown the presence of integration in 9 of 176 (5.1%) samples. In 15 
8 of 9 (88.9%) E2 region was disrupted, with the remaining one (11.1%) sample having E1 16 
region disrupted.  17 
The combined integration results obtained with both methods, DIPS and E1/E2 PCR 18 
reveal the integration in 13 of 176 (7.4%) samples. Table 2 shows the distribution of 19 
integrated or extrachromosomal genomes found in relation to the patient cytological 20 
diagnosis. There were significantly (2=4.103, p=0.0428) more integration of HPV 16 21 
genome in the study group with HSIL (CIN 2 and CIN 3) compared to the study group with 22 
LSIL (CIN 1) (Figure 2). 23 
 11 
The discordance between the findings by the two methods, DIPS and E1/E2 PCR 1 
(Table 3) is due to the fact that E1/E2 PCR cannot distinguish between mixed and 2 
extrachromosomal viral genomes, and it cannot detect the integration event in samples where 3 
the loss of viral DNA is not within regions covered by the PCR primers used in this study. 4 
Thus, the three samples determined as mixed forms by DIPS PCR were detected as 5 
extrachromosomal form by E1/E2 PCR. In addition, one sample that was classified as 6 
integrated by DIPS PCR and extrachromosomal by E1/E2 PCR had a break in the viral DNA 7 
that was not in the regions amplified by E1/E2 PCR primers (data not shown). Finally, two 8 
samples classified as integrated by E1/E2 PCR did not give conclusive result with DIPS PCR.  9 
The DIPS PCR method enabled the amplification of 11 (6.3%) fragments containing 10 
viral and cellular DNA. In 6 of those samples both ends of cellular/viral junction amplicon 11 
were successfully sequenced, while in 5 cases only one end of viral cellular/junction was 12 
resolved, so the information about affected HPV and cellular genes and scope of deletions 13 
was incomplete in those cases. Briefly, in 6 of 11 (54.5%) samples the integration was found 14 
to occur within cellular genes and also in 6 of 11 (54.5%) samples within CFS (Table 4).  15 
The HPV 16 genome in the sample 2002299 was integrated in the human genome at 16 
the position 17q23 that is the site of VMP1 gene, which codes for the transmembrane protein 17 
involved in cell apoptosis (= TMEM49; http://www.hprd.org/protein/15649).  18 
In the sample 2002458, the HPV 16 genome was integrated in the human genome at 19 
the position 1q32.2 but no particular gene or CFS was determined in this region as only the 20 
3’-end of integrated sequence was resolved. 21 
The HPV 16 genome state in the sample 2002472 was mixed, extrachromosomal and 22 
integrated. Only the 5’-end of integrated sequence was resolved. The integration was located 23 
in the 17q12 region of the human genome. Query of the UCSC database revealed the position 24 
 12 
of the integration to be 25 kb upstream of the TCF2 gene, which codes for the TCF2 protein 1 
(http://www.hprd.org/protein/08926). However, since the 3’ end of integrated sequence was 2 
not determined we cannot say for sure whether any gene was affected by this integration 3 
event.  4 
The sample 2003194 contained the HPV 16 genome integrated at the position 11q23.3 5 
of the human genome, specifically within the PVRL1 (= nectin, = HSV entry mediator C) 6 
gene; the FRA11B and FRA11G sites being both within this region.  7 
In the sample 2003217 HPV 16 DNA was integrated at the position 2q37.3 in the 8 
human genome, probably in the FRA2J site. The integration is not directly in any gene but 9 
several might be affected, namely HES2 (10 kb downstream), PER2 (20 kb downstream) and 10 
ILKAP (25-30 kb upstream). 11 
The sample 2003379 contains HPV 16 DNA integrated at the position 19p13.11 in the 12 
human genome in the FRA19B site. This particular integration is disrupting the coding region 13 
of the CHERP (= DAN16, = SCAF6; http://www.hprd.org/protein/13051) gene. 14 
In the sample 2003416, the integration of HPV 16 genome occurred at the location 15 
19q13.2 in the FRA19B site and within the CEACAM5 (= CEA, = CD66e; 16 
http://www.hprd.org/protein/00274) gene. 17 
The sample 2003417 contains HPV 16 genome in both, extrachromosomal and 18 
integrated forms. At the site of integration (1p34.3) there are no known genes and no known 19 
CFS. The nearest CFS are FRA1C (1p31.1) and FRA1A (1p36). 20 
The sample 2004077 contains HPV 16 DNA integrated at the position 7p21.1. The 21 
integration did not occur in the CFS but upon integration a part of AHR 22 
(http://www.hprd.org/protein/02596) gene is deleted. 23 
 13 
The sample 2004377 showed HPV 16 DNA to be integrated in 10q21.2 position in the 1 
human genome in the FRA10C site. The integration occurred in the noncoding regions of the 2 
MRF-2 (=  ARID5B, =  FLJ21150) gene. 3 
The sample 2004410 also contained both, integrated and extrachromosomal forms of 4 
HPV 16 DNA. The integration was found to be at the position 11p14.3, near the FRA11D site 5 
(11p14.2), but there are no known genes in this region.  6 
 7 
Discussion 8 
Most of HPV genome integration studies focused on HPV 16 and 18, the most 9 
common HPV types found in cervical cancer. In all cell lines derived from cervical cancer 10 
tissues HPV DNA is integrated in the host cell genome and this is the same in the majority of 11 
cervical cancers. The frequency of integration for cervical cancer also differs among studies, 12 
but most are around 80% [19,20]. Different HPV types also have different rates of integration 13 
with HPV 18 being integrated in almost 100% of cases, while for HPV 16 reported frequency 14 
of integration ranged from 72-83% [21,22]. 15 
Even though some studies have tried to determine the rate of integration of HPV DNA 16 
in low grade cervical neoplasia, the results are discrepant, and the frequencies of integration 17 
range from 0% [20,23] to more than 50% [24]. Thus, the goal of this study was to determine 18 
the physical state of HPV 16 genomes and the frequency of integration in samples of different 19 
grades of precancerous cervical lesions. 20 
The DIPS method detected integrated HPV 16 DNA in 8 samples, and both, 21 
extrachromosomal and integrated forms of HPV 16 DNA in 3 samples. All samples 22 
containing integrated DNA were diagnosed as HSIL (CIN 2 or 3), except one sample with 23 
unknown diagnosis, indicating that integration in LSIL (CIN1) is a very rare event.  24 
 14 
The E1/E2 PCR amplifying parts of those viral genes found integrated forms of HPV 1 
16 DNA in 9 (5.1%) samples, 8 of which showed E2 region to be disrupted with one sample 2 
having E1 region disrupted. Similar results were obtained by Watts [25] finding 72.7% of E2 3 
gene disruption in HPV 16 positive cervical cancer samples. 4 
The E1/E2 PCR method is simple and easy to perform but it cannot be used for the 5 
determination of the site of integration and it cannot distinguish between extrachromosomal 6 
and mixed viral forms. Furthermore, this method does not detect integrated copies where the 7 
loss of viral DNA is outside of regions covered with PCR primers that were used in this study. 8 
These two issues were the main cause of discrepancy in the results obtained with both 9 
methods, DIPS and E1/E2 PCR.  10 
The DIPS PCR method is rather time consuming and laborious, however it allows 11 
accurate determination of the site of integration in the human genome. On the other hand, the 12 
method is not very suitable for determining the frequency of integration, since it did not give 13 
us any conclusive result in 17.1% cases. For that reason, the results of both methods, DIPS 14 
and E1/E2 PCR are presented herein. 15 
These combined findings indicate that integration of HPV 16 DNA is not an early 16 
event as Peitsaro et al. [26] and Gallo et al. [24] suggest, them having found 50% integrated 17 
HPV forms in LSIL samples. In this study, no integration of HPV DNA in LSIL samples was 18 
found, which is in line with other studies [20,22]. In addition, the frequency of HPV DNA 19 
integration in HSIL samples (i.e. 12.8% of CIN 2 and 13% of CIN 3 samples) is similar to 20 
those obtained by Klaes et al. [20], 5% and 15% of CIN 2 and CIN 3 samples, respectively. 21 
The discrepancy of the results for CIN 2 samples might be attributed to the inability of clearly 22 
distinguishing between CIN 2 and CIN 3 grades, both of which have been classified as HSIL 23 
in the recent cytological classification [27]. 24 
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Apart from the frequency of integration, the main goal of this study was to determine 1 
the sites of integration within human genome by using the DIPS PCR method. The HPV 16 2 
integration found in this study was random as expected; it occurred once on chromosomes 2, 3 
7 and 10 and twice on chromosomes 1, 11, 17 and 19, but on different parts of chromosomes 4 
(Table 4). According to the majority of studies, the integration of HPV DNA is a random 5 
event and the place of integration does not affect the progression of the disease [10]. 6 
However, in this study HPV 16 integration occurred in many cases (54.5%) within CFS. This 7 
result is in accordance with Thorland et al. [29] who found HPV 16 integrated in the CFS in 8 
48% of their cases. Some authors consider that HPV integration in CFS, which are prone to 9 
breaks and different types of rearrangements, is the result of their greater accessibility [10]. 10 
Supporting this view is the fact that observed HPV integration near common oncogenes, like 11 
myc, TP63, FANCC, hTERT and others, was not shown to affect the expression of those 12 
genes.  13 
Yu et al. [28] created a model for HPV integration in vitro. They observed integration 14 
in the CFS in 50% of cases, some of which were identical to the observed integration sites for 15 
HPV 16 and 18 in cervical samples. They also believe that site of integration does play a role 16 
in the disease progression, and that during persistent infection HPV is integrated in many 17 
places in the genome, some of which lead to different expression of HPV oncoproteins and/or 18 
cellular genes conferring proliferative advantage to those cells and influencing disease 19 
progressions. To validate those assumptions, a large set of clinical samples with integrated 20 
genomes should be assayed and the disease progression should be closely monitored.  21 
An interesting result to note is that 6 (54.5%) of the 11 integrated samples were 22 
integrated within genes and that 3 additional cases were located 10-30 kb from genes. Most of 23 
the genes that were affected by integration in our study could be linked to the neoplastic 24 
progression in one way or another. By studying the literature we found that some of those 25 
 16 
sites were identified as targets of HPV integration in previous studies, and some of the 1 
affected genes were linked to cervical, as well as other types of cancer. 2 
Namely, 3 cases of HPV 16 integration within the fragile site FRA17B [10] have been 3 
previously found in cervical cancer specimens and one of them was in the VMP1 gene [29]. 4 
Furthermore, 5 integrations of HPV 18 in cervical cancer samples have been reported in the 5 
same region (17q23) [10]. This indicates that HPV integrations within region 17q23 are more 6 
frequent than chance would suggest, and potential disruption of the gene involved in 7 
apoptosis might be implicated in cervical cancer progression. 8 
The integration in 17q12 region was not in the fragile site, but was in proximity of the 9 
TCF2 gene. As the 3’-end of the integrated fragment was not resolved it is possible that the 10 
TCF2 gene is affected. The TCF2 protein is a transcription factor involved in the metabolism 11 
of nucleic acids and nucleotides. It has been extensively studied, and one study indicates that 12 
it could be involved in the development of ovarian cancer [30]. In addition, Wentzensen et al. 13 
[10] also reported HPV16 to be integrated in this region (17q12) in one cervical cancer 14 
sample. 15 
The HPV 16 integration within PVRL gene might also have an impact on progression 16 
of cancer. The PVRL1 is a transmembrane protein involved in cellular adhesion and Herpes 17 
Simplex virus entry [31,32]. No HPV genome integrations have been reported in this region 18 
previously, but loss of heterozigosity (LOH) of 11q23 region is common in tumors, indicating 19 
the presence of an unknown tumor suppressor gene in this region [33-36]. Lazo [37] reports 20 
LOH of 11q23 region in 38% (73/188) of cervical cancer samples. Kersemaekers et al. [36] 21 
report finding a strong correlation between LOH of 11q23 region and invasive cervical 22 
cancer. This indicates that the 11q23 region might contain metastasis suppressor gene, and 23 
since the PVRL1 gene affects cellular adhesion, it is a potential candidate for that role.  24 
 17 
The integration in FRA2J (2q37.3 locus) was mapped in the proximity of the ILKAP 1 
gene, which codes for a serine/threonine phosphatase from the phosphatase family PP2C. The 2 
ILKAP protein interacts with integrin linked kinases (ILK), which regulate integrin cellular 3 
signaling, and it is also associated with Wnt signaling pathway [38,39]. There is no published 4 
data on the HPV integration in this locus of the human genome, but again, some data suggest 5 
that LOH of 2q might influence cervical cancerogenesis [40]. 6 
The integration in FRA19B (19p13.11 locus) was found to be directly disrupting the 7 
coding region of the CHERP gene, which codes for a ribonucleoprotein situated in the 8 
endoplasmic reticulum and the cytoplasm, and it functions as a negative regulator of cellular 9 
proliferation [41,42]. There are no published data regarding the HPV integration in the 10 
19p13.11 locus.  11 
The integration of HPV 16 in FRA19A (19q13.2 locus) was mapped to CEACAM5 12 
gene. The CEACAM5 protein is a transmembrane adhesion molecule that also has a role in 13 
immune responses and apoptosis [43]. Many tumors have an elevated expression of 14 
CEACAM5 and CEACAM6 proteins, which are important for adhesion, invasion and 15 
metastasis in tumors. By blocking these proteins with monoclonal antibodies it is possible to 16 
stop the metastasis process [44,45]. Two integration events in this gene have been published, 17 
HPV 16 in a cervical cancer specimen and HPV 18 in a CIN 3 sample [10]. 18 
The integration on the short arm of chromosome 1, at 1p34.3 was not mapped to any 19 
gene or fragile site, the nearest fragile sites being FRA1C (1p31.1) and FRA1A(1p36). 20 
However, one integration event in that region has already been published [10].  21 
Another HPV 16 integration outside of CFS was mapped to the AHR gene (7p21.1 22 
locus), which codes for a transcription factor involved in the metabolism of nucleic acids and 23 
nucleotides that regulates the cellular response to aromatic hydrocarbons. It has been 24 
 18 
suggested that it also has a role in tumorgenesis and proliferation. The AHR protein represses 1 
c-myc [47]. Here again, the disruption of AHR function might influence cervical 2 
cancerogenesis. 3 
The integration of HPV 16 in FRA10C (10q21.2 locus) was found to occur in the 4 
noncoding region of MRF-2 gene. This gene contains a DNA binding domain, and although 5 
its function is still unclear [48], it is known to be involved in the differentiation of smooth 6 
muscle [49]. 7 
In case of the sample containing both, integrated and extrachromosomal forms of HPV 8 
16 DNA, the integration occurred at the position 11p14.3, in the proximity of the FRA11D. 9 
As there are no known genes in this region it is difficult to predict any changes due to the 10 
viral integration.  11 
The findings of this study show that HPV 16 genome integration is not an early event 12 
in the progression of cervical disease, and that the preferential regions of integration are the 13 
common fragile sites. This study also shows HPV genomes to often be integrated in or near 14 
cellular genes. Since most of those genes could be involved in tumor progression, this 15 
suggests that the site of integration might play a role in the rate and the nature of development 16 
of cervical cancer. By investigating the sites of HPV DNA integration we might also get some 17 
insight about cellular genes that may be involved in the progression of cervical cancer and 18 
also potentially some other types of cancer. Further research is necessary to finally resolve the 19 
timing and preferential sites of HPV integration. The real-time PCR on large number of 20 
precancerous samples would easily resolve the timing issue, while the DIPS PCR analysis of 21 
samples with integrated viral genome would answer whether there are indeed preferential 22 
integration sites. In addition, since HPV integration status indicates high risk for development 23 
and progression of cervical cancer, it should be considered for a diagnostic approach. In this 24 
case also, a method based on real-time PCR that is less time consuming and informative for 25 
 19 
both integrated and extrachromosomal states, as shown in this study to be common, would be 1 
more appropriate.   2 
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Article précis 1 
 2 
Affected cell host genes by the integrated HPV 16 sequences can be linked to different 3 
aspects of cervical tumorigenesis. 4 
 29 
Table 1 1 
Sequences of primers and their location on the HPV 16 genome 2 
Linear PCR Exponential PCR Expected amplicon size 
Primer 
5' 
nucleotide 
5' → 3' Sequence Primer 
5' 
nucleotide 
5' → 3' Sequence Primer used 5' nucleotide 
Target Sau3A I 
restriction site 
Episomal HPV 
16 amplicon 
size (bp) 
Taq I 505*** 
DIPS1 901 ACGGGATGTAATGGATGGTTTTATG DIPS1N 952 AGGGGATGCTATATCAGATGACGAG DIPS1/DIPS1N 952 3480 2573 ~ 7.5 kb 
DIPS2 1293 ATGTTACAGGTAGAAGGGCG DIPS2N 1336 AGTCAGTATAGTGGTGGAAGTG DIPS2/DIPS2N 1336 3480 2189 ~ 7.1 kb 
DIPS3 1870 ACGCCAGAATGGATACAAAGACAAAC DIPS3N 1942 ATGGTACAATGGGCCTACGATAATG DIPS3/DIPS3N 1942 3480 1583 ~ 6.5 kb 
DIPS8 3028 GTGGACATTACAAGACGTTAGCCTTG DIPS8N 3092 CATGGATATACAGTGGAAGTGCAG DIPS8/ DIPS8N 3092 3480 433 ~ 5.4 kb 
DIPS9 3702 CGTCTACATGGCATTGGACAGG DIPS9N 3767 GATAGTGAATGGCAACGTGACC DIPS9/DIPS9N 3767 4521 804 ~ 4.7 kb 
DIPS9A** 3486 CCACATCTATACCTTCATATGC DIPS9AN** 3523 CGTCTGTGTTTCTTCGGTGC DIPS9A/DIPS9AN 3523 4521 642 NA 
DIPS10 5286 CCACTTTACATGCAGCCTCACC DIPS10N 5385 CTGTACCCTCTACATCTTTATCAGG DIPS10/DIPS10N 5385 6154 814 3070 bp 
DIPS4 3302 ACCCGCATGAACTTCCCATAC DIPS4N 3193 TCAACTTGACCCTCTACCAC DIPS4/DIPS4N 3213 872 2386 2750 bp 
DIPS4A** 3480 CTTGGTCGCTGGATAGTCG DIPS4AN** 3463 CGTCTGTGTTTCTTCGGTGC DIPS4A/DIPS4AN 3463 872 2591 NA 
DIPS5 3991 AGAGGCTGCTGTTATCCACAATAG DIPS5N 3942 ATGTAGACACAGACAAAAGCAGC DIPS5/DIPS5N 3942 3480 529 3020 bp 
DIPS5A** 4361 CAGCAATAGTTTTGCCTTCAACC DIPS5AN** 4340 CCTTAGGTATAATGTCAGGTGG DIPS5A/DIPS5AN 4340 3480 905 NA 
DIPS6* 5130 GTACGCCTAGAGGTTAATGCTGG DIPS6N* 5087 CCAAAAAGTCAGGATCTGGAGC DIPS6/DIPS6N NA NA NA 3500 bp 
DIPS6A** 5021 AGCCAGACACCGGAAACC DIPS6AN** 4979 GTTTAGTGGGAGTGGTTACAAAAGC DIPS6A/DIPS6AN 4979 4541 483 NA 
DIPS7 6062 ATCCACACCTGCATTTGCTGC DIPS7N 6037 GCACTAGCATTTTCTGTGTCATCC DIPS7/DIPS7N 6043 5235 853 ~ 5.5 kb 
DIPS11 6956 GATCTTCTTTAGGTGCTGGAGG DIPS11N 6893 CCTATAAGTATCTTCTAGTGTGCC DIPS11/DIPS11N 6893 6154 784 ~ 6.4 kb 
DIPS12 379 GTATTGCTGTTCTAATGTTGTTCC DIPS12N 240 GCAAAGTCATATACCTCACGTCG DIPS12/DIPS12N 240 7017 1173 ~ 7.7 kb 
* This primer was not used in Sau3A I assay due to the presence of restriction site in the primer sequence 3 
** These primers were not used in Taq I assay 4 
***HPV 16 is cut only once by Taq I enzyme at position 505, however there are HPV 16 variants with additional Taq I sites at position 2608 and 311 5 
 30 
Table 2 1 
HPV genome status according to patient cytological diagnosis 2 
Status 
Unknown 
N (%) 
ASCUS 
N (%) 
CIN 1 
N (%) 
CIN2 
N (%) 
CIN 3 
N (%) 
HSIL 
N (%) 
Total 
N 
Episomal 10 (90.9) 38 (97.4) 32 (100) 40 (87) 43 (89.6) 83 (88.3) 163 (92.6) 
Integrated 0 (0) 1 (2.6) 0 (0) 5 (10.9) 4 (8.3) 9 (9.6) 10 (5.7) 
Mixed 1 (9.1) 0 (0) 0 (0) 1 (2.2) 1 (2.1) 2 (2.1) 3 (1.7) 
Total 11 (6.3) 39 (22.2) 32 (18.2) 46 (26.1) 48 (27.3) 94 (53.4) 176 (100) 
 3 
 31 
Table 3 1 
Comparison of E1/E2 PCR and DIPS PCR in determining HPV 2 
16 integration 3 
 
E1/E2 PCR  
Episomal Integrated 
Total 
N (%) 
D
IP
S
 P
C
R
 
Episomal 135 0 135 (76.7) 
Integrated 1 7 8 (4.5) 
Mixed 3 0 3 (1.7) 
ND 28 2 30 (17.1) 
 Total  N (%) 167 (94.9) 9 (5.1) 176 (100) 
 32 
 1 
Table 4 2 
Genomic sites of HPV 16 DNA integration 3 
Sample 
Number 
Diagnosis 
HPV 16 DNA 
form 
Deletion in HPV DNA 
Cellular DNA 
deleted 
Integration 
site 
Gene CFS 5’-end in HPV 
DNA 
3’-end in HPV 
DNA 
2002299 CIN 2 Integrated 3024 (E2) 1067 (E1) ~7.5 kb 17q23 VMP1 FRA17B 
2002458 CIN 2 Integrated ND 2383 (E1) ND 1q32.2 / / 
2002472 CIN 2 Mixed 6633 (L1) ND ND 17q12 / / 
2003194 CIN 2 Integrated 2837 (E2) 2170 (E1) 9 bp 11q23.3 PVRL1 
FRA11B and 
FRA11G 
2003217 CIN 3 Integrated 3394 (E2) 1906 (E1) 13 bp 2q37.3 / FRA2J 
2003379 CIN 3 Integrated 3902 (E5) 2897 (E2) ~5 Mb 19p13.11 CHERP FRA19B 
2003416 CIN 3 Integrated ND 2085 (E1) ND 19q13.2 CEACAM5 FRA19A 
2003417 CIN 3 Mixed 3705 (E2) 2309 (E1) ~3.4 kb 1p34.3 / / 
2004077 CIN 3 Integrated ~ 3440 (E2) 3404 (E2) ND 7p21.1 AHR / 
2004377 CIN 2 Integrated 5544 (L2) ND ND 10q21.2 MRF-2 FRA10C 
2004410 ND Mixed ND ND ND 11p14.3 / FRA11D 
 33 
Figure 1 - Position of Sau3A I and Taq I restriction sites and DIPS primers on the HPV 16 1 
genome 2 
 3 
Figure 2 – Association of cervical lesions and HPV genome status 4 
 5 
